Join her newsletter to get inspiring, empowering, and actionable information
This complexity is why metabolic treatments like GLP-1s are unlikely to alter the disease course
It now includes oral GLP-1 drugs, amylin combinations, dual agonists, triple agonists, long-acting platforms, and differentiated assets designed for durability, tolerability, access, or broader metabolic indications
Currently, only 13 states cover GLP-1s for weight loss, according to KFF
Researchers are responsible for ensuring compliance with all applicable regulations, institutional policies, and laboratory protocols
Tips for a Smooth Transition A successful switch from one GLP-1 medication to another relies on preparation and realistic expectations